| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Chief Financial Officer
1 company
Peter S Garcia last filed a Form 4 in August 2024, as Chief Financial Officer at ALXO. Peter S Garcia's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Peter S Garcia's trades have earned a strong insider score of 81/100 across 9 rated trades. Over a 12-month horizon, 77.8% of those trades were profitable, with an average 12-month return of +43.6%.
At the last filing, the largest reported position was 121,516 shares of ALXO. The ALXO filings lean toward selling, a net 78,673 shares.
Peter S Garcia has 18 Form 4 filings on record from July 2020 to August 2024, all as Chief Financial Officer at Alx Oncology (ALXO), 2020–2024.
The 48 reported transactions were 28 open-market sales, 8 option exercises, 5 option or other derivative awards and 3 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $159K and 7 sales worth about $6.6M.
The largest open-market purchase was 12,000 shares of ALXO at an average $8.53 on June 13, 2024, about $102K. Twelve months later ALXO was down 94%.
The largest open-market sale was 60,000 shares of ALXO at an average $74.15 on August 23, 2021, about $4.4M. Twelve months later ALXO was down 81%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from August 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 13, 2024 | ALXO Alx Oncology Holdings Inc | Chief Financial Officer | Buy | 12,000 | $8.53 | $102,338.40 | +10.9% | -74.2% | -93.9% | |
| Dec 29, 2023 | ALXO Alx Oncology Holdings Inc | Chief Financial Officer | Sell | 1,893 | $15.04 | $28,470.72 | -2.2% | -25.1% | -89.1% | |
| Jun 30, 2023 | ALXO Alx Oncology Holdings Inc | Chief Financial Officer | Sell | 887 | $7.34 | $6,510.58 | -1.6% | -34.1% | -19.7% | |
| Dec 29, 2022 | ALXO Alx Oncology Holdings Inc | Chief Financial Officer | Sell | 893 | $11.07 | $9,885.60 | -1.6% | -56.4% | +29.9% | |
| Oct 18, 2021 | ALXO Alx Oncology Holdings Inc | Chief Financial Officer | Sale+OE | 7,229 | $55.44 | $400,793.15 | -43.7% | -69.2% | -78.4% | |
| Sep 17, 2021 | ALXO Alx Oncology Holdings Inc | Chief Financial Officer | Sale+OE | 12,771 | $79.13 | $1,010,505.89 | -57.8% | -70.6% | -84.3% | |
| Aug 23, 2021 | ALXO Alx Oncology Holdings Inc | Chief Financial Officer | Sale+OE | 60,000 | $74.15 | $4,448,761.78 | -86.5% | -49.5% | -81.2% | |
| Aug 17, 2021 | ALXO Alx Oncology Holdings Inc | Chief Financial Officer | Sale+OE | 10,000 | $66.23 | $662,298.67 | -51.7% | -32.3% | -79.0% | |
| Jul 21, 2020 | ALXO Alx Oncology Holdings Inc | Chief Financial Officer | Buy | 3,000 | $19.00 | $57,000.00 | New | - | - |